Pre-provision of naloxone to prevent heroin overdose deaths: …. J... · Page 47 Carers – the...
Transcript of Pre-provision of naloxone to prevent heroin overdose deaths: …. J... · Page 47 Carers – the...
Page 1
Pre-provision of naloxone to prevent heroin overdose deaths: evidence, myths and UK experience
Professor John Strang
National Addiction Centre, London, UK
Page 2
Declaration (personal & institutional)
DH, NTA, Home Office, NACD, EMCDDA, WHO, UNODC, NIDA
NHS provider (community & in-patient); also Phoenix House, Lifeline, Clouds House, KCA
(Kent Council on Addictions)
Reckitt-Benckiser, Schering-Plough, Genus-Britannia, Napp, Titan, Martindale, Catalent,
Auralis, Lundbeck, Astra-Zeneca, Alkermes, UCB, Fidelity, Rusan, Mundipharma
Europe, Lannacher, Lightlake & others, including trying to work with possible pharma-
manufacturers
UKDPC (UK Drug Policy Commission), SSA (Society for the Study of Addiction); and two
Masters degrees (taught MSc and IPAS)
Work also with several charities (and received support) including Action on Addiction, and
also with J Paul Getty Charitable Trust (JPGT) and Pilgrim Trust
Page 3
caveat
I’m a doctor, not a lawyer
I’m a doctor, working with my patients
Page 4
Why does the take-home naloxone issue matter?
Overdose is the major cause of death among drug users – mainly opiates
Most heroin overdoses are witnessed
Most witnesses intervene actively (often wrongly)
Many family members witness overdose
Page 5
Structure of today’s talk:
take-away naloxone and overdose deaths
What is the problem?
When does it occur?
How could naloxone help?
Areas of confusion
Page 6
Page 7
Oxygen saturation: IV versus IM
0 10 20 30 40 50 60
90
92
94
96IV
IM
Minutes post-injection
Sp
O2
(%)
Page 8
Oxygen saturation: IV versus IM
0 10 20 30 40 50 60
90
92
94
96IV
IM
Minutes post-injection
Sp
O2
(%)
Page 9
Oxygen saturation: case study
0 10 20 30 40 50 60
84
87
90
93
96
Male, age 49Intravenous diamorphine (6 years)This dose = 120 mgDaily dose = 400mg
Minutes post-injection
Sp
O2
(%)
Page 10
WHICH DRUG?
Page 11
Drug use prevalence and Drug-related deaths: England &Wales 2011/12 (ONS)
Drug Prevalence in general
population (use in
last year, age 16-59)
No. of deaths in 2011
Cannabis 6.9%
Cocaine 2.2%
Amphetamine 0.8%
Ecstasy 1.4%
Opiates (inc heroin &
methadone)
0.3%
Page 12
Drug use prevalence and Drug-related deaths: England &Wales 2011/12 (ONS)
Drug Prevalence in general
population (use in
last year, age 16-59)
No. of deaths in 2011
Cannabis 6.9% 7
Cocaine 2.2% 112
Amphetamine 0.8% 62
Ecstasy 1.4% 13
Opiates (inc heroin &
methadone)
0.3% 1,082
Page 13
Conclusion number 1: Drugs involved with overdose
HEROIN
Heroin and sedative mixtures
Page 14
HOW COMMON?
Page 15
London PAI Study #2: 312 injectors
Personal overdose? - 117 (38%)
Witnessed overdose? - 157 (50%)
Witnessed fatal O/D? - 46 (15%)
(Strang, Griffiths, Powis, Fountain, Williamson and Gossop, Drug and Alcohol Review, 1999)
Page 16
INTERVENTION OPPORTUNITY?
Sydney - 86% had witnessed O/D
Adelaide - 70% had witnessed O/D
London PAI injectors - 50%
(London treatment sample - 83/97%)
Page 17
Conclusion number 2
Overdose is common hazard
Overdose frequently witnessed
Page 18
Resusc training and naloxone?
opiates involved?
home context?
peers present?
Page 19
Naloxone? - personal O/D
Treatment sample (n=142)
Community sample (n=312)
Ever overdosed? 78/142 (55%) 118/312 (38%)
last personal overdose…
-involved opiates
-at own or friends home own home
friends home
-in company of others
sexual partner
close friends
72/78 (92%)
61/78 (78%) 43
18
66/78 (85%)
33
27
102/118 (86%)
84/118 (80%) 52
42
95/118 (81%)
32
57
(Strang, Powis, Best, Vingoe, Griffiths, Taylor, Welch and Gossop, Addiction, 1999)
Page 20
Naloxone? -witnessed O/D
Treatment sample
(n=142)
Community sample
(n=312) Witnessing overdoses Ever witnessed overdose? Witnessed O/D in last year?
44/48* (92%)
13/48 (27%)
167/ 312 (52%)
81/312 (26%) last overdose witnessed…
-involved opiates -O/D by sexual partner close friend casual acq. stranger
44/44 (100%) 6
32 1 5
153/159*(96%) 18 84 53 10
* data collected from only 48 * data missing on 8 cases (Strang, Powis, Best, Vingoe, Griffiths, Taylor, Welch and Gossop, Addiction 1999)
Page 21
Naloxone? - witnessed fatal O/D
Treatment sample
(n=142)
Community sample
(n=312)
Witnessing fatal overdoses Ever witnessed overdose fatality?
14/48* (29%)
55/312 (18%)
last fatal O/D witnessed… -involved opiates -death of sexual partner close friend casual acquaintance stranger
14/14(100%)
34/38* (89%)
2 33 15 3
* data collected from only 48 ** data missing on 8 cases * data available from only 38 subjects
(Strang, Powis, Best, Vingoe, Griffiths, Taylor, Welch and Gossop, Addiction, 1999)
Page 22
Conclusion number 3: O/D intervention opportunity?
opiates involved? - YES
home context? - YES
peers present? - YES
Page 23
Structure of today’s talk:
take-away naloxone and overdose deaths
What is the problem?
When does it occur?
How could naloxone help?
Areas of confusion
Page 24
When in particular excess?
Post-detox and post-rehab
During methadone early treatment
* Prison release *
Page 25
Page 26
Risk of death during and after treatment
Cornish et al, BMJ 2010; 341: c5475
Page 27
When in particular excess?
Post-detox/rehab
During methadone early treatment
Prison release
Page 28
Page 29
Prevalence of drug dependence
Drug dependence prior to prison
Substance Misuse in Prisoners 2002 Singleton N, Farrell M, Meltzer H ONS.
Page 30
Page 31
Excess mortality ratio for different time periods post-release by
cause of death (Singleton, Farrell, Marsden et al 2003)
0
5
10
15
20
25
30
35
40
45
Up to
1
1 up to 2
2 up to 4
4 up to 8
8 up to 13
13 up to 26
26 up to 52
>=52Total
Time since release (w eeks)
Excess m
ort
alit
y r
atio
Drug-related deaths Not drug-related
Page 32
Structure of today’s talk:
take-away naloxone and overdose deaths
Where is the problem?
When does it occur?
How could naloxone help?
Areas of confusion
Page 33
Page 34
Pre-filled syringe 1 mg per ml, 2 ml syringe available from: Antigen, Aurum, Mayne £6.30
Page 35
First mooted:
JS - Keynote on Harm reduction - pushing at the envelope (Melbourne Harm Reduction conference, 1992) (and the linked Heather et al book)
First serious consideration:
Strang, J., Darke, S., Hall, W., Farrell, M. & Ali, R. (1996) Heroin overdose: the case for take-home naloxone? British Medical Journal,
312: 1435.
Page 36
First investigated:
Strang J, Powis B, Best D et al (1999) Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction, 94 (2): 199-204.
Page 37
Page 38
Why does the take-home naloxone issue matter?
Overdose is the major cause of death among drug users – mainly opiate
Most heroin overdoses are witnessed
Most witnesses intervene actively (often wrongly)
Many family members witness overdose
Page 39
Training - scope
Training elements
(a) how to recognise overdose
(b) how to manage situation – general
(c) how to give naloxone
Page 40
Page 41
How to Recognise Opiate Overdose
Person unconscious, cannot be woken – UNROUSABLE
CYANOSIS – BLUE lips or tongue
Not breathing at all or breathing slowly – deep snoring.
Pin point pupils
Page 42
Actions on Discovering Overdose
A – Ambulance - CALL AMBULANCE
B- Breathing - Check Airway – clear if blocked, Check breathing.
C – reCovery - If breathing, place in recovery position – if not breathing, begin basic life support
Administer naloxone
Page 43
How to inject Naloxone – intramuscular (into muscle)
Remove syringe from box and packet
Attach needle to syringe
Inject into the outer thigh, upper arm or outer part of buttock
Hold needle 90 degree above skin
Insert needle into muscle (needs pressure)
Slowly and Steadily push plunger all the way down
Put syringe back in box. Don’t cover needle
Page 44
Target audience
Anyone with possibility/probability of being in the house with opiate user at time of overdose
(family member; (parent, partner, sib, son/daughter); flatmate etc)
n.b. not just those in treatment
Page 45
Possible target populations (Training)
Non-medic drug workers
Key agency personnel
Patients
Carers
Wider clients (e.g. NSX, etc)
Users (i.e. not linked to patient status)
Strang, Kelleher et al, BMJ, 2006
Page 46
Page 47
Carers – the overlooked intervention workforce
102 carers attending 4 organisations
• 80% parents, 20% other relative/partner
• 96% of opiate users, 87% IDU, 57% in Tx,
• 1/3 used in presence of carer, 47% had past OD
• 20% of carers had witnessed an OD
• 5 had lost user to fatal OD (3 children 2 partners)
• 16% would ‘panic’ or ‘not know what to do’
• 83% expressed an interest OD management & N training
Evidence of potential to extend naloxone…
Strang, Manning, Mayet et al, (2008) Family carers and prevention of heroin overdose deaths: ……
Drugs: Education, Prevention & Policy, 15: 211-218.
Page 48
Does the naloxone ever get used?
Initial experience ……
Berlin/Jersey – about 10% used within a year
New Mexico, USA – 2/100 within few months
Chicago, USA – 52/550
Dettmer, Saunders and Strang, BMJ, 2001
Baca et al, BMJ, 2001
Bigg, BMJ, 2002
Page 49
The MRC N-ALIVE Pilot Trial: NALoxone InVEstigation
N-ALIVE Chief Investigators
Prof. John Strang, Prof. Mahesh Parmar, Prof. Sheila Bird
N-ALIVE CTU Trial Team
Dr. Angela Meade, Laura Nichols, Lizzie Armstrong, Tracey Pepple
Funding and support: MRC with research support from MHRN.
Page 50
N-ALIVE trial – pilot & main phase
N-ALIVE research trial to test/prove reduced deaths post-release
Pilot – current, ongoing (n=>500)
Main study – n=30,000 (15k + 15k)
Page 51
Heroin-related deaths account for 8% of all UK deaths in individuals aged 15-44 yrs.
One in 200 prisoners with history of heroin use by injection dies from a drugs-related death (DRD) within 2–4 weeks of leaving prison.
Current approaches have not prevented high rate of post-release overdose deaths.
Background
Page 52
Page 53
Page 54
Structure of today’s talk:
take-away naloxone and overdose deaths
Where is the problem?
When does it occur?
How could naloxone help?
Areas of confusion
Page 55
Possible concerns
Short half-life - does naloxone last long enough?
What about date-expiry?
Safety net - might it increase risk-taking?
Might witnesses be less likely to call ambulance?
Are witnesses sufficiently skilled?
Will the naloxone be available?
Might family be afraid to give injection?
Page 56
Next steps – ‘to do’ list Improve naloxone (route, device, drug)
Extend to other populations
- Non-medical drug workers (health)
- High-risk population agency staff (hostels)
- Carers
- High risk clients (not in Tx, prison release hostels)
Implementation inertia – ‘Just do it’
Page 57
Thank you